Even one dose of tocilizumab could hinder bad prognosis of cytokines storm in COVID-19 patients
Copyright © 2023 Elsevier Ltd. All rights reserved..
Severe COVID-19 pneumonia is a principal cause of death due to cascade of hyper inflammatory condition that leading to lung damage. Therefore, an effective therapy to countercurrent the surge of uncontrolled inflammation is mandatory to propose. Anti-interlukin-6 receptor antagonist monoclonal therapy, tocilizumab (TCZ) showed potential results in COVID-19 patients. This study aimed to emphasize the factors associated with mortality in COVID-19 patients that treated with tocilizumab and may influence the level of serum IL-6. A retrospective cohort study included all patients with clinical parameters that pointed to presence of cytokines storm and treated with one or more doses of TCZ beside the regular protocol of COVID-19 pneumonia. The factors that influence the mortality in addition to the level of serum IL-6 were analyzed. A total of 377 patients were included, 69.5 % of them received only one dose of TCZ which started mainly at the third day of admission. The mortality rate was 29.44 %. Regardless the time of starting TCZ, just one dose was fair enough to prevent bad consequence; OR = 0.04, P = 0.001.However, in spite of protective action of TCZ, older age and female sex were significant risk factors for mortality, P = 0.001 and 0.01 respectively, as well heart disease. Moreover, increasing the level of neutrophil, AST and IL-6 were associated with bad prognosis. In the same line, treatment with ivermectin, chloroquine and remdesivir inversely affect the level of IL-6. Early treatments of COVID-19 pneumonia with at least one dose of tocilizumab minimized the fatality rate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:173 |
|---|---|
| Enthalten in: |
Cytokine - 173(2024) vom: 18. Jan., Seite 156433 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdel-Salam Elgohary, Mohamed [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cyto.2023.156433 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364640499 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364640499 | ||
| 003 | DE-627 | ||
| 005 | 20240409232232.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cyto.2023.156433 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM364640499 | ||
| 035 | |a (NLM)37972479 | ||
| 035 | |a (PII)S1043-4666(23)00311-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abdel-Salam Elgohary, Mohamed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Even one dose of tocilizumab could hinder bad prognosis of cytokines storm in COVID-19 patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Severe COVID-19 pneumonia is a principal cause of death due to cascade of hyper inflammatory condition that leading to lung damage. Therefore, an effective therapy to countercurrent the surge of uncontrolled inflammation is mandatory to propose. Anti-interlukin-6 receptor antagonist monoclonal therapy, tocilizumab (TCZ) showed potential results in COVID-19 patients. This study aimed to emphasize the factors associated with mortality in COVID-19 patients that treated with tocilizumab and may influence the level of serum IL-6. A retrospective cohort study included all patients with clinical parameters that pointed to presence of cytokines storm and treated with one or more doses of TCZ beside the regular protocol of COVID-19 pneumonia. The factors that influence the mortality in addition to the level of serum IL-6 were analyzed. A total of 377 patients were included, 69.5 % of them received only one dose of TCZ which started mainly at the third day of admission. The mortality rate was 29.44 %. Regardless the time of starting TCZ, just one dose was fair enough to prevent bad consequence; OR = 0.04, P = 0.001.However, in spite of protective action of TCZ, older age and female sex were significant risk factors for mortality, P = 0.001 and 0.01 respectively, as well heart disease. Moreover, increasing the level of neutrophil, AST and IL-6 were associated with bad prognosis. In the same line, treatment with ivermectin, chloroquine and remdesivir inversely affect the level of IL-6. Early treatments of COVID-19 pneumonia with at least one dose of tocilizumab minimized the fatality rate | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cytokines storm | |
| 650 | 4 | |a IL-6 | |
| 650 | 4 | |a Ivermectin | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 700 | 1 | |a Ali, Asmaa |e verfasserin |4 aut | |
| 700 | 1 | |a J Alarfaj, Sumaiah |e verfasserin |4 aut | |
| 700 | 1 | |a Shahin, Hesham |e verfasserin |4 aut | |
| 700 | 1 | |a Ibrahim Zaki, Ashraf |e verfasserin |4 aut | |
| 700 | 1 | |a Medhat Hasan, Eman |e verfasserin |4 aut | |
| 700 | 1 | |a Emam Mohamed, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmoud Elkholy, Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a El-Masry, Thanaa A |e verfasserin |4 aut | |
| 700 | 1 | |a Samir Kamal, Jacklin |e verfasserin |4 aut | |
| 700 | 1 | |a Ali AbdelRahim, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Wageh Saber, Ashgan |e verfasserin |4 aut | |
| 700 | 1 | |a Seadawy, Mohamed G |e verfasserin |4 aut | |
| 700 | 1 | |a Elshishtawy, Mohamed H M |e verfasserin |4 aut | |
| 700 | 1 | |a El-Bouseary, Maisra M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cytokine |d 1994 |g 173(2024) vom: 18. Jan., Seite 156433 |w (DE-627)NLM012645575 |x 1096-0023 |7 nnns |
| 773 | 1 | 8 | |g volume:173 |g year:2024 |g day:18 |g month:01 |g pages:156433 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cyto.2023.156433 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 173 |j 2024 |b 18 |c 01 |h 156433 | ||